30 closest matches · ranked by relevance
Community-acquired Pneumonia · Bacterial Pneumonia
Primary: Percentage of Participants With Early Clinical Response at the Early Clinical Response (ECR) Visit — 89.6; 87.7; 8.6; 9.3 Percentage of participants
Community Acquired Bacterial Pneumonia
Primary: Early Clinical Response — 383; 381 Participants
Pneumonia
Primary: Use of Antibiotics in Each Group — 28; 52 participants
Community Acquired Pneumonia
Primary: Early Clinical Response (ECR) — 336; 334; 29; 31 Participants
Community Acquired Pneumonia
Primary: Early Clinical Response (ECR) — 241; 248; 29; 21 Participants
Community Acquired Pneumonia
Primary: Use of Antibiotics in Each Group — 9; 21 participants — p=0.01
Infections
Primary: Clinical Response at Study Day 4 in the Modified Intent-to-Treat (MITT) Population — 14; 8; 16; 8 participants
Community-Acquired Bacterial Pneumonia · Lung Infection of Individual Not Recently Hospitalized
Primary: Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at Test of Cure (TOC) in CE Population — 217; 178; 41; 62 Participants
Community Acquired Pneumonia (CAP)
Primary: Response Rate (Clinical Response, Data Review Committee Assessment) — 86.3; 84.5; 82.9 percentage of participants
Healthcare Associated Pneumonia
Primary: Pathogens of Healthcare Associated Pneumonia, Measured by the Number of Participants — 15; 51; 195; 269 Participants
Pneumonia
Primary: Clinical Cures in the Intent to Treat Population — 213; 224; 21; 9 Participants — p=0.0769
Pneumonia, Bacterial
Primary: Percentage of Participants With Clinical Response at Test of Cure (TOC) Visit — 90.0; 87.5; 62.5; 10.0 percentage of participants
Bacterial Pneumonia
Primary: Clinical Cure Rate at Test-of-Cure (TOC) in the Modified Intent-to-Treat Efficacy (MITTE) Populations — 244; 233; 34; 58 participants
Community-Acquired Pneumonia (CAP)
Primary: Clinical Cure in the Clinically Evaluable (CE) Population at Test of Cure (TOC) — 34; 37; 32 Participants
Community Acquired Respiratory Disease Syndrome
Primary: 60-day Mortality — 50; 47; 227; 239 Participants — p=0.635
Pneumonia
Primary: Clinical Cures in the Intent to Treat Population — 217; 206; 14; 13 Participants — p=0.5667
Pneumonia
Primary: Desirability of Outcome Ranking (DOOR) — 97; 107; 47; 42 Participants — p=<0.001
Pneumonia Childhood
Primary: Exclusive Guideline-Concordant Antibiotic Therapy, First 24 Hours — 255; 284; 174; 120 Participants
Community-acquired Pneumonia
Primary: Log Geometric Mean Area Under the Concentration Versus Time Curve (AUC) From Time 0 to 48 Hours After Dosing (AUC[0-48]) of Oral Omadacycline on Day 2 — 9.93 Hours x…
Bacterial Pneumonia
Primary: Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at the Test of Cure (TOC) in the Modified Intent to Treat Efficacy (MITTE) Population — 235; 206; 47…
Pneumonia, Bacterial · Community-acquired
Primary: Serum Cidal Activity as Tested Against Staphylococcus Aureus Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth) — 2; 4; 1; 1 Log inhibition
Pneumonia, Bacterial
Primary: Number of Patients With Clinical Success as Judged by the Investigator — 158; 145; 6; 8 Participants — p==0.499
Microbiota · Anti-bacterial Agents
Primary: Degree of Microbial Disruption: Number of Patients With Recovery of Bacterial Species Richness at 185 Days Post-antibiotics — 3; 3; 2; 3 Participants
Pneumonia · Pediatric Respiratory Diseases · Antibiotic Use
Primary: Total Pilot Trial Enrollment — 0; 1 Participants
Community-acquired Pneumonia (CAP) · Hospital-acquired Pneumonia (HAP)
Primary: Adverse Events — 10; 5; 1; 0 Participants
Bacterial Pneumonia · Community-Acquired Infections
Primary: Number of Participants With Early Clinical Response — 313; 321; 49; 47 Participants
Pneumonia Childhood
Primary: Inappropriate Disposition — 7; 6 Participants
Pneumonia, Bacterial
Primary: Number of Participants Surviving Through LFU Visit — 191; 196; 64; 57 Participants — p=0.4263
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
Bacterial Pneumonia
Primary: Percentage of Participants With All-cause Mortality (ACM) Through Day 28 in the Modified Intention-to-treat (MITT) Population — 15.9; 21.3 Percentage of participants…